On August 24, 2026, GSK PLC (NYSE: GSK) announced that the FDA has accepted for priority review its supplemental Biologics License Application (sBLA) for Jemperli, targeting untreated stage II and III mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer. The FDA’s Prescription Drug User Fee Act (PDUFA) action date is set for February 2027, with expedited assessment possible through the National Priority Voucher program.
GSK offers a dividend yield of 3.47% with a payout ratio of 57%, though dividend growth has declined by 5.7% over the past three years. The stock is modestly overvalued by 15.2% based on GuruFocus’ GF Value™ of $45.49 versus the current price of $52.41. The company holds a solid GF Score™ of 73/100, reflecting balanced financial health and operational performance. Guru 13F data shows 16 premium gurus currently hold GSK, with 11 trimming positions and 6 adding in recent quarters, signaling mixed but notable institutional interest.What’s Behind the News?
The FDA’s acceptance of GSK’s supplemental Biologics License Application for Jemperli marks a significant regulatory milestone for the company’s oncology portfolio. This priority review targets a niche but critical patient population with untreated stage II and III mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer. The application leverages promising phase II AZUR-1 trial data, which demonstrated a durable clinical complete response lasting a year without detectable cancer signs. If approved, Jemperli could strengthen GSK’s foothold in oncology, an area the company has been expanding alongside its traditional respiratory, antiviral, and vaccine segments.
GSK PLC is a major player in the pharmaceutical industry with a market capitalization of $104.97 billion. Operating primarily within the healthcare sector and drug manufacturing industry, GSK develops, manufactures, and markets a broad range of pharmaceutical products, including respiratory treatments, antivirals, vaccines, and consumer health products. The company has also been growing its presence in oncology and immunology, supported by joint ventures to expand scale in markets such as HIV.
Is GSK’s Dividend Safe and Attractive?
GSK currently offers a dividend yield of 3.47%, which is attractive relative to many peers in the healthcare sector. The payout ratio stands at 57%, indicating that the company distributes just over half of its earnings as dividends. While this level generally suggests a sustainable payout, it is important to note that GSK’s dividend growth has declined by 5.7% over the past three years, which could signal some pressure on future increases. Nevertheless, the payout ratio remains moderate, and the company’s strong operating margin expansion and cash flow generation provide a buffer for maintaining dividend payments.
Supporting this dividend thesis, GuruFocus’ GF Value™ estimates GSK’s intrinsic value at $45.49, which is 15.2% below the current market price of $52.41. This modest overvaluation suggests that while the stock may be somewhat expensive relative to its fundamentals, the dividend yield and payout ratio still offer a compelling income proposition for investors prioritizing steady cash returns. For more on GF Value™, see here.
What Does GSK’s GF Score™ Tell Us?
The GF Score™ is a composite metric that evaluates a company’s overall quality by examining financial strength, profitability, growth, valuation, and momentum. GSK’s GF Score™ of 73/100 indicates a generally healthy company with solid fundamentals but some areas for improvement.
Metric Rating GF Score™ 73 Financial Strength 5/10 Profitability 8/10 Growth 6/10 Valuation 6/10 Momentum 2/10
GSK’s strongest area is profitability, scoring 8 out of 10, supported by expanding operating margins (currently 20.7%) and a healthy net margin of 14.52%. Growth is moderate, with a 3-year revenue growth rate of 3.4% and earnings growth of 8.1% over three years. Financial strength is middling at 5/10, reflecting a moderate debt-to-equity ratio of 1.03 and an Altman Z-Score in the grey zone at 2.11, indicating some financial stress but no immediate bankruptcy risk. Momentum is the weakest factor, scoring just 2/10, suggesting limited recent price acceleration. For further details, visit the GSK stock page.
What Are Gurus and Insiders Doing with GSK?
Institutional interest in GSK remains significant but mixed. According to GuruFocus’ proprietary 13F data, 16 premium gurus currently hold GSK shares. In recent quarters, 6 gurus have added to their positions while 11 have trimmed holdings, indicating a cautious but engaged stance among top investors. This nuanced activity suggests that while some see value or growth potential, others may be taking profits or reallocating capital.
Regarding insider activity, there have been no reported insider purchases or sales in the past 3 or 12 months. The absence of insider transactions leaves institutional moves as the primary signal of confidence or concern.
What This Means for Investors
For income-focused investors, GSK presents a dividend stock with a reasonably attractive yield and a moderate payout ratio that supports sustainability despite recent negative dividend growth trends. The company’s modest overvaluation by GF Value™ tempers enthusiasm somewhat but does not negate the appeal of its cash returns. Mixed guru activity and a middling financial strength score suggest that investors should monitor developments closely, particularly regulatory progress on oncology drugs like Jemperli that could drive future growth. Overall, GSK remains a viable option for dividend investors seeking exposure to a large-cap pharmaceutical with a diversified portfolio. More insights can be found on the GSK stock page or by exploring the GuruFocus Stock Screener.
Frequently Asked Questions
What is GSK’s GF Score™?
GSK’s GF Score™ of 73/100 reflects a company with solid profitability and moderate growth, balanced by average financial strength and valuation metrics. It suggests a generally healthy business with some areas to watch.
Is GSK’s dividend safe?
With a dividend yield of 3.47%, a payout ratio of 57%, and a recent decline in dividend growth of -5.7% over three years, GSK’s dividend appears moderately safe but investors should be mindful of the slowing growth trend.
What is GSK’s P/E ratio compared to historical?
GSK’s current trailing twelve months P/E ratio is 16.26x, slightly above its 5-year median P/E of 14.02x, indicating the stock trades at a modest premium relative to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].